Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 70

1.

Master transcription factors form interconnected circuitry and orchestrate transcriptional networks in oesophageal adenocarcinoma.

Chen L, Huang M, Plummer J, Pan J, Jiang YY, Yang Q, Silva TC, Gull N, Chen S, Ding LW, An O, Yang H, Cheng Y, Said JW, Doan N, Dinjens WN, Waters KM, Tuli R, Gayther SA, Klempner SJ, Berman BP, Meltzer SJ, Lin DC, Koeffler HP.

Gut. 2019 Aug 13. pii: gutjnl-2019-318325. doi: 10.1136/gutjnl-2019-318325. [Epub ahead of print]

PMID:
31409603
2.

Ramucirumab plus pembrolizumab: can we make the maths work?

Klempner SJ, Wainberg ZA.

Lancet Oncol. 2019 Aug;20(8):1041-1043. doi: 10.1016/S1470-2045(19)30399-7. Epub 2019 Jul 10. No abstract available.

PMID:
31301961
3.

TNS1-ALK Fusion in a Recurrent, Metastatic Uterine Mesenchymal Tumor Originally Diagnosed as Leiomyosarcoma.

Lee J, Singh A, Ali SM, Lin DI, Klempner SJ.

Acta Med Acad. 2019 Apr;48(1):116-120. doi: 10.5644/ama2006-124.248.

4.

Prevalence of established and emerging biomarkers of immune checkpoint inhibitor response in advanced hepatocellular carcinoma.

Ang C, Klempner SJ, Ali SM, Madison R, Ross JS, Severson EA, Fabrizio D, Goodman A, Kurzrock R, Suh J, Millis SZ.

Oncotarget. 2019 Jun 18;10(40):4018-4025. doi: 10.18632/oncotarget.26998. eCollection 2019 Jun 18.

5.

FGFR2-Altered Gastroesophageal Adenocarcinomas Are an Uncommon Clinicopathologic Entity with a Distinct Genomic Landscape.

Klempner SJ, Madison R, Pujara V, Ross JS, Miller VA, Ali SM, Schrock AB, Kim ST, Maron SB, Dayyani F, Catenacci DVT, Lee J, Chao J.

Oncologist. 2019 Jun 27. pii: theoncologist.2019-0121. doi: 10.1634/theoncologist.2019-0121. [Epub ahead of print]

PMID:
31249137
6.

Progress and challenges in HER2-positive gastroesophageal adenocarcinoma.

Zhao D, Klempner SJ, Chao J.

J Hematol Oncol. 2019 May 17;12(1):50. doi: 10.1186/s13045-019-0737-2. Review.

7.

Keeping Checkpoint Inhibitors in Check.

Catenacci DVT, Hochster H, Klempner SJ.

JAMA Netw Open. 2019 May 3;2(5):e192546. doi: 10.1001/jamanetworkopen.2019.2546. No abstract available.

PMID:
31050772
8.

Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for Therapy.

Parikh AR, He Y, Hong TS, Corcoran RB, Clark JW, Ryan DP, Zou L, Ting DT, Catenacci DV, Chao J, Fakih M, Klempner SJ, Ross JS, Frampton GM, Miller VA, Ali SM, Schrock AB.

Oncologist. 2019 Apr 30. pii: theoncologist.2019-0034. doi: 10.1634/theoncologist.2019-0034. [Epub ahead of print]

PMID:
31040255
9.

Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer.

Schrock AB, Ouyang C, Sandhu J, Sokol E, Jin D, Ross JS, Miller VA, Lim D, Amanam I, Chao J, Catenacci D, Cho M, Braiteh F, Klempner SJ, Ali SM, Fakih M.

Ann Oncol. 2019 Jul 1;30(7):1096-1103. doi: 10.1093/annonc/mdz134.

PMID:
31038663
10.

Real-Time Targeted Genome Profile Analysis of Pancreatic Ductal Adenocarcinomas Identifies Genetic Alterations That Might Be Targeted With Existing Drugs or Used as Biomarkers.

Singhi AD, George B, Greenbowe JR, Chung J, Suh J, Maitra A, Klempner SJ, Hendifar A, Milind JM, Golan T, Brand RE, Zureikat AH, Roy S, Schrock AB, Miller VA, Ross JS, Ali SM, Bahary N.

Gastroenterology. 2019 Jun;156(8):2242-2253.e4. doi: 10.1053/j.gastro.2019.02.037. Epub 2019 Mar 2.

11.

Variety Is the Spice of Life, but Maybe Not in Gastroesophageal Adenocarcinomas.

Klempner SJ, Catenacci DVT.

Cancer Discov. 2019 Feb;9(2):166-168. doi: 10.1158/2159-8290.CD-18-1447.

PMID:
30737213
12.

A phase 1 study of veliparib, a PARP-1/2 inhibitor, with gemcitabine and radiotherapy in locally advanced pancreatic cancer.

Tuli R, Shiao SL, Nissen N, Tighiouart M, Kim S, Osipov A, Bryant M, Ristow L, Placencio-Hickok V, Hoffman D, Rokhsar S, Scher K, Klempner SJ, Noe P, Davis MJ, Wachsman A, Lo S, Jamil L, Sandler H, Piantadosi S, Hendifar A.

EBioMedicine. 2019 Feb;40:375-381. doi: 10.1016/j.ebiom.2018.12.060. Epub 2019 Jan 8.

13.

Low ATM expression and progression-free and overall survival in advanced gastric cancer patients treated with first-line XELOX chemotherapy.

Klempner SJ, Bhangoo MS, Luu HY, Kim ST, Chao J, Kim KM, Lee J.

J Gastrointest Oncol. 2018 Dec;9(6):1198-1206. doi: 10.21037/jgo.2018.09.04.

14.

Initial Report of Second-Line FOLFIRI in Combination with Ramucirumab in Advanced Gastroesophageal Adenocarcinomas: A Multi-Institutional Retrospective Analysis.

Klempner SJ, Maron SB, Chase L, Lomnicki S, Wainberg ZA, Catenacci DVT.

Oncologist. 2019 Apr;24(4):475-482. doi: 10.1634/theoncologist.2018-0602. Epub 2018 Nov 23.

PMID:
30470690
15.

Carving out another slice of the pie: Exceptional response to single agent imatinib in an asian female never-smoker with advanced NSCLC with a de-novo PDGFR-α N848 K mutation.

Klempner SJ, Gowen K, Lee TK, Zhu VW, Schrock AB, Miller VA, Ali SM, Ou SI.

Lung Cancer. 2018 Oct;124:86-89. doi: 10.1016/j.lungcan.2018.07.043. Epub 2018 Jul 31.

16.

Beyond microsatellite testing: assessment of tumor mutational burden identifies subsets of colorectal cancer who may respond to immune checkpoint inhibition.

Fabrizio DA, George TJ Jr, Dunne RF, Frampton G, Sun J, Gowen K, Kennedy M, Greenbowe J, Schrock AB, Hezel AF, Ross JS, Stephens PJ, Ali SM, Miller VA, Fakih M, Klempner SJ.

J Gastrointest Oncol. 2018 Aug;9(4):610-617. doi: 10.21037/jgo.2018.05.06.

17.

Refining the management of resectable esophagogastric cancer: FLOT4, CRITICS, OE05, MAGIC-B and the promise of molecular classification.

Chuang J, Gong J, Klempner SJ, Woo Y, Chao J.

J Gastrointest Oncol. 2018 Jun;9(3):560-572. doi: 10.21037/jgo.2018.03.01. Review.

18.

Advances in immuno-oncology biomarkers for gastroesophageal cancer: Programmed death ligand 1, microsatellite instability, and beyond.

Lin EM, Gong J, Klempner SJ, Chao J.

World J Gastroenterol. 2018 Jul 7;24(25):2686-2697. doi: 10.3748/wjg.v24.i25.2686. Review.

19.

Receptor Tyrosine Kinase Fusions and BRAF Kinase Fusions are Rare but Actionable Resistance Mechanisms to EGFR Tyrosine Kinase Inhibitors.

Schrock AB, Zhu VW, Hsieh WS, Madison R, Creelan B, Silberberg J, Costin D, Bharne A, Bonta I, Bosemani T, Nikolinakos P, Ross JS, Miller VA, Ali SM, Klempner SJ, Ou SI.

J Thorac Oncol. 2018 Sep;13(9):1312-1323. doi: 10.1016/j.jtho.2018.05.027. Epub 2018 Jun 5.

20.

Toward optimizing outcomes in Her2-positive gastric cancer: timing and genomic context matter.

Klempner SJ, Chao J.

Ann Oncol. 2018 Apr 1;29(4):801-802. doi: 10.1093/annonc/mdy066. No abstract available.

PMID:
29462252
21.

Tumor Mutational Burden Guides Therapy in a Treatment Refractory POLE-Mutant Uterine Carcinosarcoma.

Bhangoo MS, Boasberg P, Mehta P, Elvin JA, Ali SM, Wu W, Klempner SJ.

Oncologist. 2018 May;23(5):518-523. doi: 10.1634/theoncologist.2017-0342. Epub 2018 Jan 31.

22.

Hybrid Capture-Based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Cancers of the Gastrointestinal Tract or Anus.

Schrock AB, Pavlick D, Klempner SJ, Chung JH, Forcier B, Welsh A, Young L, Leyland-Jones B, Bordoni R, Carvajal RD, Chao J, Kurzrock R, Sicklick JK, Ross JS, Stephens PJ, Devoe C, Braiteh F, Ali SM, Miller VA.

Clin Cancer Res. 2018 Apr 15;24(8):1881-1890. doi: 10.1158/1078-0432.CCR-17-3103. Epub 2018 Jan 23.

23.

Cis-oriented solvent-front EGFR G796S mutation in tissue and ctDNA in a patient progressing on osimertinib: a case report and review of the literature.

Klempner SJ, Mehta P, Schrock AB, Ali SM, Ou SI.

Lung Cancer (Auckl). 2017 Dec 6;8:241-247. doi: 10.2147/LCTT.S147129. eCollection 2017.

24.

Correlating programmed death ligand 1 (PD-L1) expression, mismatch repair deficiency, and outcomes across tumor types: implications for immunotherapy.

Kim ST, Klempner SJ, Park SH, Park JO, Park YS, Lim HY, Kang WK, Kim KM, Lee J.

Oncotarget. 2017 Aug 24;8(44):77415-77423. doi: 10.18632/oncotarget.20492. eCollection 2017 Sep 29.

25.

The impact of gender, race, socioeconomic status, and treatment on outcomes in esophageal cancer: A population-based analysis.

Tran PN, Taylor TH, Klempner SJ, Zell JA.

J Carcinog. 2017 Sep 18;16:3. doi: 10.4103/jcar.JCar_4_17. eCollection 2017.

26.

Neoadjuvant Chemotherapy Improves Survival in Patients with Clinical T4b Colon Cancer.

Dehal A, Graff-Baker AN, Vuong B, Fischer T, Klempner SJ, Chang SC, Grunkemeier GL, Bilchik AJ, Goldfarb M.

J Gastrointest Surg. 2018 Feb;22(2):242-249. doi: 10.1007/s11605-017-3566-z. Epub 2017 Sep 20.

PMID:
28933016
27.

Pulse Dose Erlotinib and Zuckerguss Improvement in EGFR-Mutant NSCLC.

Mehta P, Hamid O, Klempner SJ.

J Thorac Oncol. 2017 Dec;12(12):1857-1858. doi: 10.1016/j.jtho.2017.07.024. Epub 2017 Jul 31. No abstract available.

28.

PD-1 and PD-L1 as emerging therapeutic targets in gastric cancer: current evidence.

Tran PN, Sarkissian S, Chao J, Klempner SJ.

Gastrointest Cancer. 2017;7:1-11. doi: 10.2147/GICTT.S113525. Epub 2017 May 5.

29.

ALK on my mind: alectinib takes an early lead in managing intracranial disease in non-small cell lung cancer with ALK rearrangements.

Tran PN, Klempner SJ.

Ann Transl Med. 2017 Apr;5(7):173. doi: 10.21037/atm.2017.03.47. No abstract available.

30.

Profile of rociletinib and its potential in the treatment of non-small-cell lung cancer.

Tran PN, Klempner SJ.

Lung Cancer (Auckl). 2016 May 18;7:91-97. doi: 10.2147/LCTT.S94337. eCollection 2016. Review.

31.

Comprehensive Genomic Profiling Aids in Distinguishing Metastatic Recurrence from Second Primary Cancers.

Weinberg BA, Gowen K, Lee TK, Ou SI, Bristow R, Krill L, Almira-Suarez MI, Ali SM, Miller VA, Liu SV, Klempner SJ.

Oncologist. 2017 Feb;22(2):152-157. doi: 10.1634/theoncologist.2015-0511. Epub 2017 Feb 13.

32.

Rapamycin-insensitive companion of mTOR (RICTOR) amplification defines a subset of advanced gastric cancer and is sensitive to AZD2014-mediated mTORC1/2 inhibition.

Kim ST, Kim SY, Klempner SJ, Yoon J, Kim N, Ahn S, Bang H, Kim KM, Park W, Park SH, Park JO, Park YS, Lim HY, Lee SH, Park K, Kang WK, Lee J.

Ann Oncol. 2017 Mar 1;28(3):547-554. doi: 10.1093/annonc/mdw669.

PMID:
28028034
33.

Focus on Alectinib and Competitor Compounds for Second-Line Therapy in ALK-Rearranged NSCLC.

Tran PN, Klempner SJ.

Front Med (Lausanne). 2016 Nov 30;3:65. eCollection 2016. Review.

34.

Targeting the Phosphatidylinositol-3-kinase Pathway in Gastric Cancer: Can Omics Improve Outcomes?

Tran P, Nguyen C, Klempner SJ.

Int Neurourol J. 2016 Nov;20(Suppl 2):S131-140. Epub 2016 Nov 22. Review.

35.

HER2 Transmembrane Domain (TMD) Mutations (V659/G660) That Stabilize Homo- and Heterodimerization Are Rare Oncogenic Drivers in Lung Adenocarcinoma That Respond to Afatinib.

Ou SI, Schrock AB, Bocharov EV, Klempner SJ, Haddad CK, Steinecker G, Johnson M, Gitlitz BJ, Chung J, Campregher PV, Ross JS, Stephens PJ, Miller VA, Suh JH, Ali SM, Velcheti V.

J Thorac Oncol. 2017 Mar;12(3):446-457. doi: 10.1016/j.jtho.2016.11.2224. Epub 2016 Nov 27.

36.

Emergence of Preexisting MET Y1230C Mutation as a Resistance Mechanism to Crizotinib in NSCLC with MET Exon 14 Skipping.

Ou SI, Young L, Schrock AB, Johnson A, Klempner SJ, Zhu VW, Miller VA, Ali SM.

J Thorac Oncol. 2017 Jan;12(1):137-140. doi: 10.1016/j.jtho.2016.09.119. Epub 2016 Sep 22.

37.

Intracranial Activity of Cabozantinib in MET Exon 14-Positive NSCLC with Brain Metastases.

Klempner SJ, Borghei A, Hakimian B, Ali SM, Ou SI.

J Thorac Oncol. 2017 Jan;12(1):152-156. doi: 10.1016/j.jtho.2016.09.127. Epub 2016 Sep 28.

38.

Broad Detection of Alterations Predicted to Confer Lack of Benefit From EGFR Antibodies or Sensitivity to Targeted Therapy in Advanced Colorectal Cancer.

Rankin A, Klempner SJ, Erlich R, Sun JX, Grothey A, Fakih M, George TJ Jr, Lee J, Ross JS, Stephens PJ, Miller VA, Ali SM, Schrock AB.

Oncologist. 2016 Nov;21(11):1306-1314. doi: 10.1634/theoncologist.2016-0148. Epub 2016 Sep 28.

39.

Focal Hepatic Fluorodeoxyglucose Uptake Mimics Liver Metastasis Following External Beam Radiation for Gastroesophageal Cancers: A Case and Review of the Literature.

Wei R, Chaurasia A, Yu S, Lall C, Klempner SJ.

J Clin Imaging Sci. 2016 Aug 9;6:30. doi: 10.4103/2156-7514.188089. eCollection 2016.

40.

Radiation dermatitis caused by a bolus effect from an abdominal compression device.

Connor M, Wei RL, Yu S, Sehgal V, Klempner SJ, Daroui P.

Med Dosim. 2016 Autumn;41(3):221-4. doi: 10.1016/j.meddos.2016.02.003. Epub 2016 Jun 2.

PMID:
27264694
41.

Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-Responsive ALK-Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ Hybridization.

Ali SM, Hensing T, Schrock AB, Allen J, Sanford E, Gowen K, Kulkarni A, He J, Suh JH, Lipson D, Elvin JA, Yelensky R, Chalmers Z, Chmielecki J, Peled N, Klempner SJ, Firozvi K, Frampton GM, Molina JR, Menon S, Brahmer JR, MacMahon H, Nowak J, Ou SH, Zauderer M, Ladanyi M, Zakowski M, Fischbach N, Ross JS, Stephens PJ, Miller VA, Wakelee H, Ganesan S, Salgia R.

Oncologist. 2016 Jun;21(6):762-70. doi: 10.1634/theoncologist.2015-0497. Epub 2016 May 31.

42.

Moving molecular subtypes to the clinic in gastric cancer.

Chao J, Lee J, Klempner SJ.

Transl Cancer Res. 2016 Jun;5(Suppl 1):S25-S30. doi: 10.21037/tcr.2016.05.21. No abstract available.

43.

Alectinib induced CNS radiation necrosis in an ALK+NSCLC patient with a remote (7 years) history of brain radiation.

Ou SH, Weitz M, Jalas JR, Kelly DF, Wong V, Azada MC, Quines O, Klempner SJ.

Lung Cancer. 2016 Jun;96:15-8. doi: 10.1016/j.lungcan.2016.03.008. Epub 2016 Mar 26.

PMID:
27133743
44.

Comprehensive genomic profiling of anal squamous cell carcinoma reveals distinct genomically defined classes.

Chung JH, Sanford E, Johnson A, Klempner SJ, Schrock AB, Palma NA, Erlich RL, Frampton GM, Chalmers ZR, Vergilio J, Rubinson DA, Sun JX, Chmielecki J, Yelensky R, Suh JH, Lipson D, George TJ Jr, Elvin JA, Stephens PJ, Miller VA, Ross JS, Ali SM.

Ann Oncol. 2016 Jul;27(7):1336-41. doi: 10.1093/annonc/mdw152. Epub 2016 Apr 6.

PMID:
27052656
45.

BRAFV600E Mutations in High-Grade Colorectal Neuroendocrine Tumors May Predict Responsiveness to BRAF-MEK Combination Therapy.

Klempner SJ, Gershenhorn B, Tran P, Lee TK, Erlander MG, Gowen K, Schrock AB, Morosini D, Ross JS, Miller VA, Stephens PJ, Ou SH, Ali SM.

Cancer Discov. 2016 Jun;6(6):594-600. doi: 10.1158/2159-8290.CD-15-1192. Epub 2016 Apr 5.

46.

Bone mineral density loss in thoracic and lumbar vertebrae following radiation for abdominal cancers.

Wei RL, Jung BC, Manzano W, Sehgal V, Klempner SJ, Lee SP, Ramsinghani NS, Lall C.

Radiother Oncol. 2016 Mar;118(3):430-6. doi: 10.1016/j.radonc.2016.03.002. Epub 2016 Mar 15.

PMID:
26993414
47.

Targeting the MET Pathway in Gastric and Oesophageal Cancers: Refining the Optimal Approach.

Lee J, Tran P, Klempner SJ.

Clin Oncol (R Coll Radiol). 2016 Aug;28(8):e35-44. doi: 10.1016/j.clon.2016.01.009. Epub 2016 Feb 13. Review.

PMID:
26880063
48.

A novel acquired ALK F1245C mutation confers resistance to crizotinib in ALK-positive NSCLC but is sensitive to ceritinib.

Kodityal S, Elvin JA, Squillace R, Agarwal N, Miller VA, Ali SM, Klempner SJ, Ou SH.

Lung Cancer. 2016 Feb;92:19-21. doi: 10.1016/j.lungcan.2015.11.023. Epub 2015 Dec 3.

PMID:
26775591
49.

Moving molecularly directed therapies to the first-line in ALK-positive lung cancer: crizotinib is just the beginning.

Klempner SJ, Raufi A, Ou SH.

Transl Lung Cancer Res. 2015 Oct;4(5):649-52. doi: 10.3978/j.issn.2218-6751.2015.07.03.

50.

Identification of BRAF Kinase Domain Duplications Across Multiple Tumor Types and Response to RAF Inhibitor Therapy.

Klempner SJ, Bordoni R, Gowen K, Kaplan H, Stephens PJ, Ou SH, Ali SM.

JAMA Oncol. 2016 Feb;2(2):272-4. doi: 10.1001/jamaoncol.2015.4437. No abstract available.

PMID:
26562024

Supplemental Content

Loading ...
Support Center